Hi, #ASCO21 world. As you get bombarded with news of the remarkable new therapies, I request you to kindly read these 3 papers to put things into context. 1. Trials that are flawed in design, analysis, and interpretation can give false signal of benefit- esmoopen.com/article/S2059-… 1
2. Drugs that are claimed to be "well-tolerated" or having a "favourable" or "Acceptable" toxicity profiles are usually not so. These are almost misnomers. Look into the safety data yourself. bmj.com/content/363/bm… 2
Patients in LMICs are still dying not because they didn't have access to the newest checkpoint inhibitor but because they didn't have access to surgery/radiation/pathology/chemo and other basic services. #cancergroundshot#globaloncologythelancet.com/journals/lanon…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
I’m officially starting my faculty career in academic oncology as an Associate Professor @queensoncology@QueensUHealth from June 1st, 2021. I’m super excited about it, and very thankful to everyone who has had a role in making this happen. This is a twitter thread of gratitude.
First of all, I’m extremely thankful to my mentor Chris Booth. Honestly, Chris is the reason I moved to Queen’s. He has not only supported me in my career but has also been a great friend and advisor. I feel lucky to be working with him.
My immense gratitude to my mentor and department head @scottrberry. Scott has been incredibly supportive and helpful, and left no stones unturned to make this happen. He was never busy to not have time to listen to me. He’s a boss you’d want to work hard for.
It was my pleasure sharing some thoughts on communication skills in oncology with the participants of @ecancer#Kolkata21 meeting today morning. The video is already available to watch for those interested: ecancer.org/en/video/9670-…
With special thanks to @ChernyNathan@scottrberry and @ramsedhom for providing me advice/thoughts/slides to make this talk possible. I myself learned a lot in this process.
Many thanks to @HealthCommunic2 for organizing the event. Missed meeting all dear friends and colleagues in person, hopefully next year we can.
For the first time, we now have official data on the commonest cancers in Kathmandu by incidence and mortality in different subgroups of population. ascopubs.org/doi/full/10.12…
The population-based cancer registry has only just started in Nepal, and there are plenty of room for improvement. But I hope this provides the foundation for stronger work in the future. ascopubs.org/doi/full/10.12…
Very happy to see this announcement today from @FDAOncology . Early approval based on surrogate and appropriate action upon failure to confirm clinical benefit in confirmatory trial is the mandate of accelerated approval. fda.gov/news-events/fd…
Several of our works @PORTAL_Research have previously highlighted that this follow-through has not been happening. Failure to act when drugs fail to improve clinical benefit in confirmatory trials breaks the social compromise of AA. I will share 2 imp papers in this regard.
First, in this @JAMAInternalMed paper we published last year, we show that confirmatory trials do not confirm clinical benefit using survival endpoints and even when confirmatory trials fail, no actions are usually taken. jamanetwork.com/journals/jamai…@akesselheim
This thread is going to be a collection of all my #globaloncology papers, primarily for my own reference to bookmark for quick access but also, just in case, it is helpful for any colleague with an interest in global oncology. 1/
This is probably one of the most important papers we’ve ever published. This paper in British Journal of Hematology highlights the story of how Bone Marrow Transplant services started in Nepal under @Poudyalbishesh ‘s initiative. onlinelibrary.wiley.com/doi/full/10.11…
Seems like this is the time to look back upon your year. Here’s a thread on my tweets from 2019 that I’d like to share again with the new followers. No particular order. Here’s the first one: medscape.com/viewarticle/91… I learned a lot by reading all the comments to this piece.